Tandem Posts 58% Q4 Margin, Eyes Pharmacy Shift with $70–80M Headwind and “Toby” FDA Bid
Tandem reported a record Q4 gross margin of 58%, driven by price increases, rising Mobi volume and early pharmacy supply sales that doubled QoQ. It expects a $70–80 million 2026 revenue headwind from pharmacy pay-as-you-go, 20% of pumps through pharmacies and FDA submission of tubeless Mobi “Toby” in Q2.
1. Record Q4 Gross Margin and Drivers
Tandem achieved a 58% gross margin in the fourth quarter, its highest to date, driven by price increases, increased Mobi pump volume and the initial shift of t:slim X2 supplies into pharmacy. Pharmacy sales, though under 5% of the install base, doubled from Q3 to Q4, contributing significantly to margin gains.
2. International Direct Sales Expansion
The company launched direct sales in Switzerland, Austria and the U.K., removing distribution intermediaries and securing at least a 30% average selling price uplift in these markets. Direct channels are expected to account for about 15% of total sales in 2026 as reimbursement collection shifts in-house.
3. U.S. Pharmacy Model and Tubeless Mobi Pipeline
Tandem is transitioning U.S. durable pump supplies to a pay-as-you-go pharmacy model, which will incur a $70–80 million revenue headwind in 2026 in exchange for roughly double reimbursement over four years. The company forecasts 20% of pumps via pharmacies next year and plans FDA submission of its tubeless Mobi “Toby” cartridge in Q2 for a second-half commercial launch.